BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel. Show more

16 Hartum St, Jerusalem, 9777516, Israel

Medical Devices
Healthcare
Start AI Chat

Market Cap

487.3M

52 Wk Range

$7.84 - $26.63

Previous Close

$24.12

Open

$24.48

Volume

76,755

Day Range

$23.27 - $24.48

Enterprise Value

218.9M

Cash

71.54M

Avg Qtr Burn

N/A

Insider Ownership

6.17%

Institutional Own.

30.77%

Qtr Updated

09/30/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date